Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMA with… →

IMA Key Statistics

As of Sep 4, 2026

Trading

Open: $4.87
Previous Close: $4.89
Day's Range: 4.73–4.97
52-Week Range: 3.94–9.47
Volume: 15.50K

Valuation

Market Cap: $55.16M
P/E Ratio: unprofitable
EPS (ttm): −4.73

Financials (FY)

Revenue (FY): $800.00K−77.14%
Net Income (FY): −$45.35M
Profit margin: 0.00%
Shares Outstanding: 11.37M
1-Year Return: −42.60%

Dividend and dates

Avg Volume: 11.12K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IMA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−60.81%−78.79%−25.94%−16.75%−64.94%−29.71%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−29.71%
2025	−64.94%
2024	−16.75%
2023	−25.94%
2022	−78.79%
2021 (partial year)	−60.81%

As of September 4, 2026.

IMA Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$800.00K	−$45.35M	−5668.6%
2024	$3.50M	−$36.57M	−1044.8%
2023	$7.96M	−$21.15M	−265.6%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$800.00K	—	−$48.45M	−$45.35M	−5668.6%
2024	$3.50M	—	−$37.00M	−$36.57M	−1044.8%
2023	$7.96M	—	−$21.93M	−$21.15M	−265.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IMA Valuation vs Biotechnology Median

Median of 656 stocks

Metric	IMA	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ImageneBio, Inc. (IMA) carries a market capitalisation of $55.16M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 18 employees.

IMA last closed at $4.85 on September 4, 2026. That is −$0.04 (−0.72%) against the previous close. Over the past 52 weeks the price has ranged from $3.94 to $9.47. The latest close sits 23.1% above that 52-week low.

Financial Health

In fiscal 2025, ImageneBio, Inc. reported revenue of $800.00K. That is −77.14% against the prior fiscal year, when revenue was $3.50M. The same year closed with a net loss of $45.35M. The reported profit margin is 0%. Trailing earnings per share are −4.73.

Across the 3 fiscal years on file, revenue moves from $7.96M in 2023 to $800.00K in 2025. Of those 3 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned −42.60%. Measured over 5 years, that is −50.85% a year compounded. Annualized volatility over the trailing 5 years is 88.33%.

Growth & Income

The record shows no dividend for IMA.

Across the complete calendar years on file, 2024 returned −16.75% and 2022 returned −78.79%. Of the 4 complete calendar years on file, 0 finished higher. So far in 2026 the price is −29.71%.

Peer Comparison

ImageneBio, Inc. (IMA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
ImageneBio, Inc.	IMA	$55.16M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. ImageneBio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About ImageneBio, Inc.

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Visit website →

ImageneBio, Inc. (IMA) Stock Analysis